These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 14598082

  • 1. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
    Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A.
    Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082
    [Abstract] [Full Text] [Related]

  • 2. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
    Arabia G, Zappia M, Bosco D, Crescibene L, Bagalà A, Bastone L, Caracciolo M, Scornaienghi M, Quattrone A.
    Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
    [Abstract] [Full Text] [Related]

  • 3. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A.
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case.
    Carecchio M, Collini A, Comi C, Cantello R, Bhatia KP, Monaco F.
    Mov Disord; 2010 Aug 15; 25(11):1760-2. PubMed ID: 20645401
    [No Abstract] [Full Text] [Related]

  • 7. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.
    Arch Neurol; 2006 Feb 15; 63(2):205-9. PubMed ID: 16476808
    [Abstract] [Full Text] [Related]

  • 8. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
    Harder S, Baas H.
    Clin Pharmacol Ther; 1998 Aug 15; 64(2):183-91. PubMed ID: 9728899
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
    Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Cirò-Candiano IC, Gambardella A, Quattrone A.
    Arch Neurol; 2005 Apr 15; 62(4):601-5. PubMed ID: 15824260
    [Abstract] [Full Text] [Related]

  • 11. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A.
    Clin Neuropharmacol; 1999 Apr 15; 22(6):351-5. PubMed ID: 10626097
    [Abstract] [Full Text] [Related]

  • 12. Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
    Müller T, Muhlack S.
    Parkinsonism Relat Disord; 2010 Dec 15; 16(10):688-9. PubMed ID: 20719554
    [No Abstract] [Full Text] [Related]

  • 13. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA, Gachoud JP.
    Praxis (Bern 1994); 1995 Oct 24; 84(43):1235-8. PubMed ID: 7481341
    [Abstract] [Full Text] [Related]

  • 14. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA, McDermott MP, Messing S.
    Arch Neurol; 2006 Dec 24; 63(12):1756-60. PubMed ID: 17172616
    [Abstract] [Full Text] [Related]

  • 15. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
    Clin Neuropharmacol; 1999 Dec 24; 22(4):220-5. PubMed ID: 10442252
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
    Nagayama H, Ueda M, Kumagai T, Tsukamoto K, Nishiyama Y, Nishimura S, Hamamoto M, Katayama Y.
    Parkinsonism Relat Disord; 2011 Mar 24; 17(3):150-2. PubMed ID: 21172738
    [Abstract] [Full Text] [Related]

  • 18. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2009 Mar 24; 165(8-9):718-27. PubMed ID: 19150100
    [Abstract] [Full Text] [Related]

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr 24; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 20. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F, Vacca L, Ruggieri S, Olanow CW.
    Arch Neurol; 2005 Jun 24; 62(6):905-10. PubMed ID: 15956161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.